{"nctId":"NCT01253811","briefTitle":"Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency","startDateStruct":{"date":"2011-01"},"conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"count":6,"armGroups":[{"label":"rFXIII 35 IU/kg","type":"EXPERIMENTAL","interventionNames":["Drug: catridecacog"]}],"interventions":[{"name":"catridecacog","otherNames":["recombinant factor XIII"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed participation in trial F13CD-3760 (NCT01230021)\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to trial product or related products\n* Known history of development of inhibitors against FXIII (factor XIII)\n* Hereditary or acquired coagulation disorder other than FXIII congenital deficiency\n* Platelet count (thrombocytes) less than 50X10e9 / L\n* Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus\n* Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis\n* Any disease or condition which, judged by the trial physician, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome including renal and/or liver dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Treatment Emergent (Serious and Non-serious) Adverse Events","description":"An adverse event was described as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Treatment emergent adverse events (serious and non-serious), defined as adverse events occurring from first trial product administration to the end of the subject's participation in the trial.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Development of Anti-rFXIII Antibodies, Including Inhibitors.","description":"All subjects who received rFXIII were monitored for the frequency of development of anti-rFXIII antibodies. Samples passed through 2 tiers of ELISA testing: an initial screen with a specific cut-off point (including \\~5% false positives) and a second confirmatory assay for samples yielding a result above the screening cut-off point. If samples were confirmed as antibody positive in the confirmation assay, an inhibitor assay was also carried out to detect functional inhibitors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Biochemistry: Creatinine","description":"Clinical laboratory assessments for creatinine at week 24 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.20","spread":"8.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.00","spread":"6.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.67","spread":"5.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.00","spread":"4.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.50","spread":"5.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.00","spread":"6.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.17","spread":"9.79"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Biochemistry: Urea","description":"Clinical laboratory assessments for urea at week 24 to end ot trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":"1.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.99","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.52","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Biochemistry: Alanine Aminotransferase (ALAT)","description":"Clinical laboratory assessments for ALAT at week 24 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.75","spread":"5.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.20","spread":"2.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.40","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"3.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.33","spread":"12.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.00","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.00","spread":"3.94"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Biochemistry: Aspartate Aminotransferase (ASAT)","description":"Clinical laboratory assessments for ASAT at week 24 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.75","spread":"5.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.20","spread":"10.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.20","spread":"8.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.25","spread":"1.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.00","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.00","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.00","spread":"3.61"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Haematology: Haemoglobin","description":"Clinical values for haemoglobin collected from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.366","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.624","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.138","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.262","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.635","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.821","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.717","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.759","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.048","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Haematology: Leucocytes","description":"Clinical laboratory values for leucocytes collected from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.367","spread":"2.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.373","spread":"1.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.387","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.863","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.643","spread":"1.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.027","spread":"2.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.850","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.275","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.605","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Haematology: Thrombocytes","description":"Clinical laboratory values for thrombocytes collected from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"316.3","spread":"50.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296.0","spread":"54.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277.0","spread":"93.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"283.3","spread":"41.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332.3","spread":"107.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"269.7","spread":"102.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324.3","spread":"44.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307.0","spread":"15.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"321.3","spread":"60.45"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Haematology: Erythrocytes","description":"Clinical laboratory values for erythrocytes collected from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.863","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.745","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.587","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.505","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.628","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.247","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.627","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.875","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.662","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Assessments: Haematology: Haematocrit","description":"Clinical laboratory values for haematocrit collected from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.07","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.05","spread":"1.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.83","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.80","spread":"2.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.85","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.83","spread":"8.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":"3.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.40","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.45","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Physical Examinations","description":"Number of subjects in percentage with changes in values of physical examinations from week 0 to end of trial visit were collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Vital Signs: Systolic BP (Blood Pressure)","description":"Values collected for systolic BP from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.0","spread":"13.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.0","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.3","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.0","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.7","spread":"10.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.0","spread":"12.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.3","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.7","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.3","spread":"11.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":"13.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.5","spread":"19.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.4","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.7","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.7","spread":"10.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.2","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.6","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.0","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.7","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.7","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.0","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Vital Signs: Diastolic BP (Blood Pressure)","description":"Values collected for diastolic BP from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":"16.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.2","spread":"11.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"Vital Signs: Pulse","description":"Values collected for pulse from week 0 to end of trial visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.2","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":"16.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.2","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.5","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.8","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.3","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.7","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.2","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108.3","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":"22.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":"23.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.5","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.0","spread":"15.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.8","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":"18.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":"16.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":"16.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":"11.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.7","spread":"11.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":"16.8"}]}]}]},{"type":"SECONDARY","title":"Rate (Number Per Subject Year) of All Bleeding Episodes Requiring Treatment With a FXIII Containing Product Other Than Recombinant Factor XIII.","description":"The rate (number per subject year) of all spontaneous, traumatic and intracranial bleeding episodes requiring treatment with FXIII-containing products during the rFXIII treatment period was assessed for treatment period.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["Pyrexia","Diarrhoea","Upper respiratory tract infection","Contusion","Fall"]}}}